English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, July 6, 2018
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
Wednesday, July 4, 2018
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series
Monday, July 2, 2018
エーザイ、第43回日本睡眠学会定期学術集会においてレンボレキサントの不眠障害を対象とした実薬比較臨床第III相試験の結果を口頭発表予定
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder
Friday, June 22, 2018
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」を発売
エーザイ、「MSCI日本株女性活躍指数(WIN)」の構成銘柄に選定
Thursday, June 21, 2018
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
Thursday, June 14, 2018
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
Wednesday, June 13, 2018
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575